FINWIRES · TerminalLIVE
FINWIRES

UnitedHealth, CVS, Cigna Seen Benefiting From Utilization Trends, AI Upside, Morgan Stanley Says

By

UnitedHealth (UNH), CVS Health (CVS) and Cigna (CI) are among the managed-care companies that could benefit from improving utilization trends and potential artificial intelligence-driven efficiency gains across the healthcare system, Morgan Stanley said in a note Thursday.

The firm said early signs of softer utilization have supported recent gains in managed-care stocks. The group has delivered a series of medical-loss-ratio beats in Q1 and some companies raising guidance. However, it noted that investors are still awaiting clearer confirmation of underlying trends and utilization signals remaining mixed ahead of Q2 results.

AI adoption is increasingly embedded across managed-care operations, including prior authorization, call centers, provider portals, care management, pharmacy utilization and payment integrity.

Morgan Stanley said UnitedHealth stands out as a leading "AI enabler," particularly through Optum Insight initiatives, which support both efficiency gains and potential revenue upside.

The firm's scenario analysis assumes 0.5% to 2.0% AI-driven insurance margin expansion, which could translate into an illustrative 18% to 71% EPS upside across managed-care companies. It added that administrative workflows, particularly prior authorization, remain key areas of automation potential.

Morgan Stanley boosted its price targets on UnitedHealth, CVS Health, Elevance Health (ELV), Centene (CNC), Molina Healthcare (MOH), and Humana (HUM).

Price: $399.90, Change: $+22.90, Percent Change: +6.07%

Related Articles

Wire

Nexalin Technology Wins US Patent Protecting Neurostimulation Method Through 2042

Nexalin Technology (NXL) said the US Patent and Trademark Office issued a patent expected to provide core intellectual property protection for its dynamic frequency stimulation method through 2042, strengthening its competitive position in deep-brain neurostimulation for depression and insomnia.The patent covers methods including transcranial alternating current stimulation, the company said Thursday in a statement.Price: $0.50, Change: $-0.03, Percent Change: -5.41%

$NXL
Wire

Rollins' Q2 Organic Growth, Margins to Accelerate Despite Higher Fuel Costs, RBC Says

Rollins' (ROL) organic growth in Q2 is likely to accelerate along with incremental margins despite near-term pressures from elevated fuel costs, RBC Capital Markets analysts said in a note emailed Thursday.Analysts said that Google search trends for "Pest Control" remain elevated compared with historical levels, with unique visits to pest control websites up 23% in April from a year earlier.RBC said that warmer and drier weather conditions in March and April have also likely increased pest activity, further supporting industry tailwinds.For Rollins, analysts expect margin expansion into the high-20% range in Q2, driven by accelerating organic growth, normalization of insurance and claims expenses, and operating leverage from higher volumes.RBC maintained its outperform rating and a $67 price target on the stock.Price: $46.37, Change: $+0.58, Percent Change: +1.27%

$ROL
Wire

CrowdStrike's Cyber-AI Strategy Continues to Play Out, Wedbush Says

CrowdStrike's (CRWD) cyber-AI strategy continues to play out, with expansive pipeline for its cyber-AI product portfolio driving bookings pipeline, Wedbush Securities said in a Thursday note.The company reported Q1 results featuring slight beats across the board while slightly raising its FY27 guidance, the note said.CrowdStrike was the only company to secure both Anthropic's and OpenAI's cyber defense projects, pointing to the rising need for cybersecurity ecosystems for AI deployments, it said."We continue to believe that CRWD's position as the gold standard of cybersecurity remains firmly unchanged," the report said, pointing to its Falcon platform.Wedbush kept its outperform rating while raising its price target to $720 from $700 to reflect significant momentum for itsplatform approach.Price: $694.10, Change: $-53.51, Percent Change: -7.16%

$CRWD